Nordic Nanovector ASA: Mandatory notification of trade - primary insiders

On 9 December 2016, Ludvik Sandnes, who is the chairman of the board of directors Nordic Nanovector ASA (the "Company") purchased 1000 shares in the Company at an average price of NOK 115.00 per share. Following this transaction, Ludvik Sandnes owns 126,000 shares in the Company and holds 21,604 restricted stock units in the Company.

This information is subject to duty of disclosure pursuant to Section 4-2 of the Norwegian Securities Trading Act



About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at